Taxotere News and Research

RSS
Taxotere is a drug used together with other drugs to treat certain types of breast cancer, stomach cancer, prostate cancer, and certain types of head and neck cancer. It is also being studied in the treatment of other types of cancer. Taxotere is a type of mitotic inhibitor. Also called docetaxel.
European Commission approves Pfizer’s first oncology biosimilar

European Commission approves Pfizer’s first oncology biosimilar

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

FDA approves non-alcoholic Docetaxel Injection

FDA approves non-alcoholic Docetaxel Injection

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Meridian reports positive pre-IND meeting with FDA for ML061

Meridian reports positive pre-IND meeting with FDA for ML061

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Power of taxane-based chemotherapy drugs may be potentially underestimated

Power of taxane-based chemotherapy drugs may be potentially underestimated

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

Azaya announces final results from ATI-1123 Phase I study on cancers

Azaya announces final results from ATI-1123 Phase I study on cancers

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Milestone for Starpharma's drug delivery program

Milestone for Starpharma's drug delivery program

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA